Pancreatic Cancer Oncologists
Shanghai's leading medical oncologists — mRNA vaccine pioneers, ASCO presenters, national guideline authors, and precision medicine researchers.
Ruijin Hospital
上海交通大学医学院附属瑞金医院Dr. Jun Zhang
张俊
Professor · Chief Physician · PhD Supervisor · Head of Medical Oncology Department · Deputy Researcher, Shanghai Institute of Digestive Surgery
Key architect of Ruijin's 21.2% five-year survival rate — the world's best published outcome for pancreatic cancer (global average: 9–12%). Head of Medical Oncology at the world's largest pancreatic cancer center. Published the world's first mRNA tumor vaccine targeting KRAS G12V in solid tumors (Cell Research, 2024, IF 28.1). First treated patient: 31% tumor reduction after 3 cycles, 17 months disease-free, 27 months overall survival. Also identified NDUFB8 and CEMIP2 as predictive biomarkers for chemotherapy response (Cell Discovery), validated in 3 independent international cohorts. Sits on China's National Committee for Cancer Standardized Diagnosis and Treatment (Chemotherapy Section). Awards: National Science & Technology Progress Award (2nd class), Huaxia Medical Science Award (1st class), 2x Shanghai Science & Technology Progress Award (1st class).
Dr. Xinjing Wang
王新景
Physician · MD, PhD in Surgery · Pancreatic Surgery Department (mentored by Prof. Shen Baiyong)
Co-first author on the landmark Cell Research paper describing the world's first KRAS G12V mRNA tumor vaccine combined with pembrolizumab in advanced solid tumors. The mRNA vaccine is not a research concept — it is a treatment being actively administered to patients at Ruijin under clinical protocols. Dr. Wang directly handles patient inquiries for mRNA vaccine eligibility on Chinese medical platforms. For patients with KRAS G12V-mutant pancreatic cancer (present in ~40% of PDAC) and HLA-A*11:01 (~20–25% of Chinese population), this vaccine may be a treatment option. Research focus: pancreatic cancer surgery, PNETs, mRNA vaccine clinical translation.
Fudan University Shanghai Cancer Center
复旦大学附属肿瘤医院
Dr. Miaoyan Wei
魏妙艳
Attending Physician · PhD in Oncology · MD Anderson Cancer Center Visiting Scholar · Pancreatic Tumor Comprehensive Treatment Department
Trained at MD Anderson Cancer Center — consistently ranked the world's top oncology institution. Holds a rare dual Master's in Surgical Medicine + PhD in Oncology. Led a Phase II clinical trial of fruquintinib + nab-paclitaxel + gemcitabine for PDAC with liver metastasis — selected for ASCO presentation. Co-reviewer of ASCO 2025 pancreatic cancer precision medicine highlights alongside Prof. Xu Jin. Co-author of the 2020 China Pancreatic Cancer Comprehensive Diagnosis and Treatment Guidelines. Research also covers ctDNA-guided adjuvant therapy and pancreatic NET treatment. Practices within Fudan's Pancreatic Tumor Comprehensive Treatment Department — 2,250+ pancreatic resections in 2023, 45,000+ comprehensive treatment visits/year.
Dr. Heli Gao
高鹤丽
Chief Physician · Pancreatic Tumor Comprehensive Treatment Department · Fudan University Shanghai Cancer Center
Embedded medical oncologist within Dr. Xu Xiaowu's surgical team — manages neoadjuvant and adjuvant chemotherapy as part of Fudan's integrated surgical-medical pathway. Documented case: 47-year-old with borderline resectable PDAC — after 3 cycles under Dr. Gao's management, tumor shrank 39.3%, CA199 dropped 78.8%, enabling R0 resection via laparoscopic Whipple. Co-author of the 2020 China Pancreatic Cancer Guidelines — the national standard that shapes treatment across hundreds of hospitals. Research on ACSS2/BCL6/P53 axis mediating chemotherapy resistance in PanNETs (PMID: 41786280). Also manages biliary tract cancer and PNET systemic therapy.
Changhai Hospital
海军军医大学附属长海医院Dr. Shiwei Guo
郭世伟
Associate Chief Physician · PhD in Surgery · Postdoctoral Fellow in Statistics · MD Anderson Visiting Scholar · Pancreatic-Hepatobiliary-Splenic Surgery
Rare combination: PhD in Surgery + Postdoctoral Fellowship in Statistics — gives him both clinical depth and biostatistical rigor. Trained at MD Anderson Cancer Center. Pioneered China's first individualized neoantigen peptide vaccine for pancreatic cancer at Changhai Hospital. Built one of China's largest pancreatic cancer multi-omics databases integrating genomic, transcriptomic, proteomic, and clinical outcome data. Pioneered individualized drug sensitivity screening — testing patient tumor-derived organoids against panels of chemo/targeted/immuno agents. Published data on KN046 (PD-L1/CTLA-4 dual antibody) in advanced pancreatic cancer — 8 months stable disease in a patient refractory to FOLFIRINOX. Among China's first cohort of certified genetic physicians. Works within Dr. Jin Gang's MDT team.
Nanjing Drum Tower Hospital
南京大学医学院附属鼓楼医院
Prof. Juan Du
杜娟
Chief Physician · Professor · PhD Supervisor · Director of Pancreatic-Biliary Oncology Subspecialty, Cancer Center
Lead investigator of the PAAG regimen (NCT06051851) — a quadruplet therapy of penpulimab + anlotinib + nab-paclitaxel + gemcitabine that extends median PFS to 7.7 months in metastatic pancreatic cancer, a 71% improvement over standard AG chemotherapy (P<0.001). The randomized PAAG data was selected for 2026 ASCO Gastrointestinal Cancers Symposium. Serves as member of the CSCO Pancreatic Cancer Expert Committee, editorial board member of JCO Chinese Edition (Biliary Tract Oncology), and member of Chinese Anti-Cancer Association Precision Therapy Committee. Author of one monograph and co-author of five oncology textbooks including an English monograph. Holds 4 national invention patents. Awarded the Jiangsu Province Medical Technology Introduction Award (1st Class), Jiangsu Cancer Association Science and Technology Award (2nd Class), and Nanjing Medical Technology Introduction Award (2nd Class). Published in Signal Transduction and Targeted Therapy, Cell Reports Medicine, Clinical Cancer Research, and other top international journals.
Disclaimer: Doctor profiles are based on publicly available information from hospital websites, published literature, and professional society records. MedInSh is not affiliated with any hospital or physician. All information is subject to change — verify directly with the hospital's international department before making treatment decisions. This website does not constitute medical advice.